Recent studies investigating the use of a bispecific antibody against EGFR and HER3, MEHD7945A, demonstrated robust capability of overcoming resistance to both erlotinib and cetuximab in NSCLC and HNSCC cell models [50]. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.